Gerard Hascoet
Venture Partners @ Sofinnova Partners
Paris, France
Gerard Hascoet is a Series C investor at Sofinnova Partners in Paris focused on Health Care and Medical Device. Gerard Hascoet is the Executive Chairman of MD Start.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Gerard Hascoet invests in
Stages Gerard Hascoet invests in
Countries Gerard Hascoet invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Series C
- $33M–$43M
Investment Focus
Industry
- Health Care 2 (40%)
- Medical Device 2 (40%)
- Manufacturing 1 (20%)
- Emergency Medicine 1 (20%)
Stage
- Series C 2 (40%)
- Series A 1 (20%)
- Series B 1 (20%)
- Series D 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularizationefforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach. | $39.3M / Series D / Apr 05, 2022 | ||
| The CorWave LVAD utilizes an undulating disc wave pumping mechanism, replacing the high speed, high shear impeller of current continuous flow rotary pumps. The result is much less trauma to the blood, reducing clotting and bleeding complications. The high frequency actuation of the Corwave pump provides for pulsatile flow that mimics the action ofthe native heart. Current LVADs provide only continuous flow with no significant pulsation, due to the high inertia of their rotors. Its low power consumption and small size will facilitate totally implantablity with the incorporation of a wireless energy transfer system. | $43.2M / Series C / Jan 06, 2021 | ||
| LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularizationefforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach. | $33.4M / Series C / Apr 16, 2018 | ||
| The CorWave LVAD utilizes an undulating disc wave pumping mechanism, replacing the high speed, high shear impeller of current continuous flow rotary pumps. The result is much less trauma to the blood, reducing clotting and bleeding complications. The high frequency actuation of the Corwave pump provides for pulsatile flow that mimics the action ofthe native heart. Current LVADs provide only continuous flow with no significant pulsation, due to the high inertia of their rotors. Its low power consumption and small size will facilitate totally implantablity with the incorporation of a wireless energy transfer system. | $17.1M / Series B / Nov 04, 2016 | ||
| The CorWave LVAD utilizes an undulating disc wave pumping mechanism, replacing the high speed, high shear impeller of current continuous flow rotary pumps. The result is much less trauma to the blood, reducing clotting and bleeding complications. The high frequency actuation of the Corwave pump provides for pulsatile flow that mimics the action ofthe native heart. Current LVADs provide only continuous flow with no significant pulsation, due to the high inertia of their rotors. Its low power consumption and small size will facilitate totally implantablity with the incorporation of a wireless energy transfer system. | $3.5M / Series A / Jul 10, 2013 |
Co-Investors
About Sofinnova Partners
Sofinnova Partners is a venture capital firm that invests in the life sciences sector, from seed to later-stage.The firm manages over €2 billion of assets dedicated to life science investing and actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential topositively impact its collective future. It invests in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations with a focus on Life Sciences (Biopharmaceuticals / Biotech, Medical Devices, Industrial Biotechnology). Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. They sit on the boards of their portfolio companies and play an active role from the formation phase alongside entrepreneurs.It was headquartered in Paris, Ile-de-France in 1972.
Sofinnova Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alain Tingaud
Venture Partner
|
|||
Cedric Moreau
Partner
|
|||
Dominique Verdier
Operations
|
|||
Edward Kliphuis
Partner
|
|||
Jacques Theurillat
Partner, Crossover fund
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Gerard Hascoet invest in?
Gerard Hascoet invests primarily in Health Care, Medical Device and Manufacturing startups, most often at Series C and Series A stage. Most of the 5 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Gerard Hascoet's check size?
Gerard Hascoet typically joins rounds of $33M–$43M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Gerard Hascoet participates in.
How do I contact Gerard Hascoet?
Public channels for Gerard Hascoet include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Gerard Hascoet last invest?
The most recent investment recorded for Gerard Hascoet closed in Apr 2022. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
